We are live on ! Find out more
MDCX icon

Medicus Pharma
MDCX

1.93 USD
+0.05
2.66%
At close Updated Nov 2, 4:00 PM EST
Pre-market
After hours
1.96
+0.03
1.55%
1 day
2.66%
5 days
-22.8%
1 month
-76.02%
3 months
-87.18%
6 months
-86.52%
Year to date
-97.59%
1 year
-98.35%
5 years
-98.54%
10 years
-98.54%
 

About: Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.

Employees: 16

Healthcare Drug Manufacturers - General

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 33.3%
Neutral 61.1%
Negative 5.6%
Neutral
GlobeNewsWire
7 days ago
Medicus Pharma to Present at BioFuture and Global Biotechnology Summit
Company's Executive Chairman and CEO to Speak on Cancer Therapeutics Spotlight Panel at BioFuture in NYC and Deliver Keynote Address at Global Biotechnology Summit in Abu Dhabi Company's Executive Chairman and CEO to Speak on Cancer Therapeutics Spotlight Panel at BioFuture in NYC and Deliver Keynote Address at Global Biotechnology Summit in Abu Dhabi
Medicus Pharma to Present at BioFuture and Global Biotechnology Summit
Neutral
GlobeNewsWire
8 days ago
Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Nasdaq closes the minimum bid price matter confirming that the Company has regained compliance Nasdaq closes the minimum bid price matter confirming that the Company has regained compliance
Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Positive
Proactive Investors
26 days ago
Medicus Pharma targets partnerships and clinical milestones as oncology pipeline advances
Medicus Pharma (NASDAQ:MDCX) is positioning its precision oncology-led pipeline for a series of clinical and regulatory milestones, with partnerships and licensing deals central to the next phase of development, the company said in a shareholder update marking its third anniversary.  The Nasdaq-listed biotech said its priorities are to advance selected clinical and regulatory milestones, align organizational costs with those priorities, and pursue licensing and co-development opportunities.
Medicus Pharma targets partnerships and clinical milestones as oncology pipeline advances
Neutral
GlobeNewsWire
26 days ago
Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value
PHILADELPHIA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today provided a shareholder update celebrating its third anniversary, highlighting three years of progress, focused on execution and capital efficient drug development.
Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value
Neutral
Proactive Investors
1 month ago
Medicus Pharma files streamlined Phase 2b/3 prostate cancer trial design with FDA
Medicus Pharma (NASDAQ:MDCX) has submitted a seamless Phase 2b/3 registration-intent protocol to the US Food and Drug Administration for Teverelix, its long-acting GnRH antagonist for advanced prostate cancer patients at increased cardiovascular risk.  The company said the stage-gated design starts with about 80 randomized patients, replacing a previously FDA-cleared, stand-alone 40-patient open-label dose-optimization study.
Medicus Pharma files streamlined Phase 2b/3 prostate cancer trial design with FDA
Neutral
GlobeNewsWire
1 month ago
Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company's capital-efficient development strategy Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company's capital-efficient development strategy
Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
Negative
Proactive Investors
1 month ago
Medicus Pharma to focus SkinJect development exclusively on Gorlin syndrome patients
Medicus Pharma (NASDAQ:MDCX) said it will focus future internally sponsored clinical development of SkinJect exclusively on Gorlin syndrome patients with multiple basal cell carcinoma lesions and will conclude further development in sporadic/nodular basal cell carcinoma. The decision builds on the company's portfolio strategy announced earlier this month, under which Medicus is concentrating resources on programs offering the most compelling risk-adjusted opportunity.
Medicus Pharma to focus SkinJect development exclusively on Gorlin syndrome patients
Neutral
GlobeNewsWire
1 month ago
Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
PHILADELPHIA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd.
Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
Positive
Proactive Investors
1 month ago
Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress across its SkinJect program and a co-development and licensing opportunity with Pfizer, with CEO Raza Bokhari highlighting clinical, partnership and funding developments as the company sharpens its focus on precision oncology and capital-efficient drug development. Bokhari said final SkinJect results published on ClinicalTrials.gov had confirmed the 200-microgram patch as the dose to be taken forward into further registrational studies.
Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI
Positive
Proactive Investors
1 month ago
Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment
Medicus Pharma (NASDAQ:MDCX) said a completed Phase 2 study of its SkinJect therapy showed all 90 enrolled patients finished treatment without discontinuations, data the company says will guide its next-stage registrational trial in a rare genetic skin cancer syndrome. The randomized, double-blind, multicenter trial enrolled patients across 10 US investigative sites, comparing two dose levels of SkinJect against a device-only microneedle comparator.
Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment
See News Rankings
Price charts implemented using Lightweight Charts™